The effect of multiplanar loading on the intradiscal pressure of the whole human spine: systematic review and meta-analysis

Association of the FGF4L2 retrogene with fibrocartilaginous embolic myelopathy in dogs

BACKGROUND

Fibrocartilaginous embolic myelopathy (FCE) is a well-documented condition in dogs although rarely reported in chondrodystrophic breeds. Genetic associations have not been defined.

OBJECTIVES

Define the association of the chondrodystrophy-associated FGF4L2 retrogene with histopathologically confirmed cases of FCE.

ANIMALS

Ninety-eight dogs with a histopathologic diagnosis of FCE.

METHODS

Retrospective multicenter study. Dogs were genotyped for the FGF4L2 and FGF4L1 retrogenes using DNA extracted from formalin-fixed, paraffin-embedded tissue. Associations between breed, FCE and retrogene status were investigated with reference to a hospital population and known breed and general population allele frequencies.

RESULTS

FGF4L2 genotype was defined in 89 FCE cases. Fibrocartilaginous embolic myelopathy was present in 22 dogs from FGF4L2-segregating breeds with allele frequencies of ≥5%; however, all dogs were wild type. Two Labrador retrievers with FCE carried FGF4L2 alleles. Frequency of the FGF4L2 allele was significantly (P < .001) and negatively associated with FCE relative to predicted hospital-population dogs. FCE was overrepresented in Boxer, Great Dane, Yorkshire Terrier, Bernese Mountain Dog, Miniature Schnauzer, Rottweiler, and Shetland Sheepdog breeds.

CONCLUSIONS AND CLINICAL IMPORTANCE

Study data based on genotypically and histopathologically defined cases support the historical observation that FCE is uncommon in chondrodystrophic dog breeds. FGF4 plays an important role in angiogenesis and vascular integrity; anatomical studies comparing chondrodystrophic and non-chondrodystrophic dogs might provide insight into the pathogenesis of FCE.

Added value of motion capture technology for occupational health and safety innovations

Ergonomic principles in production assembly and manufacturing operations have become an essential part of comprehensive health and safety innovations. We aim to provide new insights into occupational health and safety innovations and how they utilise biomechanical methods and cutting-edge motion capture technology by assessing movements at a workplace. The practical goal is to quantify a connection between work exposure and ergonomic risk measures to determine biomechanical risk factors of diseases or health-related disorders objectively. The target group consisted of 62 factory employees working in manufacturing (26 participants on 12 devices) or assembly areas (36 participants on 9 devices). Body posture, body parts position, movements, energy cost and workloads were assessed using an inertial motion capture (MC) system. MC technology accurately assesses the operator’s movements. The proposed methodology could complement ergonomic procedures in the design of workstations, which is the added value of the motion capture technology for occupational health and safety innovations.